Health
Biotech Updates After ESMO Conference
Updates from the European Society for Medical Oncology (ESMO) conference include Moderna and Merck's race to submit a personalized cancer vaccine for FDA approval. The developments could have significant implications for future cancer treatments.
Coverage timeline — 1 article
STAT News
Moderna and Merck are racing to submit their personalized cancer vaccine for FDA approval, expected in 2027, according to Moderna CEO Stéphane Bancel.
2026-10-26 13:38 UTC